ZB004 / Zenas BioPharma, Xencor - LARVOL DELTA

A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers (ACR Convergence 2024) - "This study demonstrated that ZB004 was safe and well tolerated at all doses studied. Observed ZB004 PK and target engagement warrants continued clinical development."

Clinical • P1 data • PK/PD data • CD80 • CTLA4 • IL2

A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Zenas BioPharma (USA), LLC | Active, not recruiting ➔ Completed

Trial completion